TY - JOUR
T1 - 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
T2 - A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
AU - Ommen, Steve R.
AU - Ho, Carolyn Y.
AU - Asif, Irfan M.
AU - Balaji, Seshadri
AU - Burke, Michael A.
AU - Day, Sharlene M.
AU - Dearani, Joseph A.
AU - Epps, Kelly C.
AU - Evanovich, Lauren
AU - Ferrari, Victor A.
AU - Joglar, José A.
AU - Khan, Sadiya S.
AU - Kim, Jeffrey J.
AU - Kittleson, Michelle M.
AU - Krittanawong, Chayakrit
AU - Martinez, Matthew W.
AU - Mital, Seema
AU - Naidu, Srihari S.
AU - Saberi, Sara
AU - Semsarian, Christopher
AU - Times, Sabrina
AU - Waldman, Cynthia Burstein
N1 - Publisher Copyright:
© 2024 by the American Heart Association, Inc.
PY - 2024/6/4
Y1 - 2024/6/4
N2 - AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy"provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy. METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy"have been updated with new evidence to guide clinicians.
AB - AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy"provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy. METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy"have been updated with new evidence to guide clinicians.
KW - AHA Scientific Statements
KW - athlete
KW - atrial fibrillation
KW - cardiac myosin inhibitors
KW - cardiovascular magnetic resonance imaging
KW - diastolic dysfunction
KW - echocardiography
KW - exercise, exercise stress testing
KW - family screening
KW - genetics
KW - hypertrophic cardiomyopathy
KW - implantable cardioverter defibrillator
KW - left ventricular outflow tract obstruction
KW - occupation
KW - physical activity
KW - pregnancy
KW - rhythm monitoring
KW - risk stratification
KW - sarcomeric genes
KW - septal alcohol ablation
KW - septal reduction therapy
KW - shared decision-making
KW - sports, sudden cardiac death
KW - surgical myectomy
KW - systolic dysfunction
KW - ventricular arrhythmias
UR - http://www.scopus.com/inward/record.url?scp=85195228461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85195228461&partnerID=8YFLogxK
U2 - 10.1161/CIR.0000000000001250
DO - 10.1161/CIR.0000000000001250
M3 - Review article
C2 - 38718139
AN - SCOPUS:85195228461
SN - 0009-7322
VL - 149
SP - e1239-e1311
JO - Circulation
JF - Circulation
IS - 23
ER -